Oxford Immunotec slams Qiagen, Quest with patent suits; Burning Rock scores $23M for cancer tests;

> Oxford Immunotec is suing diagnostic heavyweights Qiagen ($QGEN), Quest Diagnostics ($DGX) and LabCorp ($LH) for infringing patents for its TB test. Story (reg. req.)

> MDxHealth unveiled positive data for its bladder cancer liquid biopsy tool, showing the test had a negative predictive value of 98.3% in a group of 154 patients. Statement

> BioTime's ($BTX) OncoCyte subsidiary is teaming up with The Wistar Institute to develop a noninvasive, blood-based test for the early detection of lung cancer. More

> China's Burning Rock Biotech roped in $23 million to develop its solid tumor cancer tests. Story

> CombiMatrix ($CBMX) scored approval from the New York State Department of Health to market its prenatal diagnosis test in the state. Statement

And Finally… The U.K.'s NHS approved cancer-sniffing dogs for a prostate cancer trial after a study found that the animals could detect prostate tumors in urine in 93% of cases. Story

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.